Fig. 4: Protective effects of Fc-M1R-01 against VACV challenge via intraperitoneal injection in mice.
From: Identification of neutralizing nanobodies protecting against poxvirus infection
a Experimental design: Balb/c mice were intranasally (IN) challenged with a lethal dose of VACV, following which they were administered intraperitoneally (IP) with 10 mg/kg of Fc-M1R-01 or an anti-GP73 antibody served as a control at days 0 and 2. The mice were then monitored for survival. At 5 days post-infection, lungs, spleens, and blood were collected for subsequent analysis. b Time course of body weight changes in Balb/c mice (n = 5 per group). c Survival curves of mice (n = 5 per group). d Spleen-to-body weight ratio (mg/g), n = 5; bars indicate the mean ± SEM. e, f Virus titers in the blood (e) and lungs (f) were determined. Bars represent the mean ± SEM of mice (n = 4). g The H&E staining of lung sections from each group. Scale bars, 300 µm. A one-way ANOVA test was employed for significance analysis. Statistical significance was shown as *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
